Sickle cell disease (SCD) is a chronic inflammatory disorder accompanied by chronic pain. In addition to ongoing pain and hyperalgesia, vaso-occlusive crises-induced pain can be chronic or episodic. Because analgesics typically used to treat pain are not very effective in SCD, opioids, including morphine, are a primary treatment for managing pain in SCD but are associated with many serious side effects, including constipation, tolerance, addiction, and respiratory depression. Thus, there is a need for the development of novel treatments for pain in SCD. In this study, we used the Townes transgenic mouse model of SCD to investigate the antinociceptive efficacy of the bivalent ligand, MCC22, and compared its effectiveness with morphine. MCC22 consists of a muopioid receptor agonist and a chemokine receptor-5 (CCR5) antagonist that are linked through a 22-atom spacer. Our results show that intraperitoneal administration of MCC22 produced exceptionally potent dose-dependent antihyperalgesia as compared to morphine, dramatically decreased evoked responses of nociceptive dorsal horn neurons, and decreased expression of proinflammatory cytokines in the spinal cord. Moreover, tolerance did not develop to its analgesic effects after repeated administration. In view of the extraordinary potency of MCC22 without tolerance, MCC22 and similar compounds may vastly improve the management of pain associated with SCD.
Introduction
Sickle cell disease (SCD) is one of the most common inherited diseases, which results from a point mutation in hemoglobin that causes the polymerization of hemoglobin S, giving red blood cells their characteristic sickle shape. 18 Hemolysis, inflammation, oxidative stress, vaso-occlusion, and chronic pain are characteristics of SCD. 29, 45, 49 Vaso-occlusive crises can occur in response to inflammation, hypoxic conditions, infections, and surgery. Vaso-occlusive crises pain can be chronic or episodic, often requiring hospitalizations and analgesics. 51 Opioids, particularly morphine, are commonly used to manage pain in SCD 4, 14 but are problematic because of their serious side effects, including tolerance, addiction, and respiratory depression. Thus, there is a need for the development of novel approaches to treat pain in SCD.
Mouse models of SCD allow for investigation into mechanisms underlying pain and evaluation of novel therapeutics. HbSS BERK and HbSS Townes mice exhibit robust hyperalgesia to mechanical, heat, and cold stimuli, as well as deep tissue hyperalgesia, which are worsened by hypoxia/reoxygenation. 8, 31, 37 Sickle mice, like patients, have elevated markers of inflammation including white blood cell counts, serum amyloid P, and cytokines. 5 Electrophysiological studies showed that nociceptors 27, 66 and dorsal horn neurons 10 are sensitized in sickle mice. Furthermore, sickle mice exhibited activated astrocytes and microglia in the spinal cord. 68 In the spinal cord, proinflammatory cytokines released by glial cells contribute to pain and hyperalgesia, including neuropathic pain, 19, 42, 55, 78 by increasing synaptic strength 12 that leads to sensitization of spinal nociceptive neurons. 32 Furthermore, proinflammatory cytokines counteract the analgesia produced by opioids. 67, 70 One chemokine that is important in spinal nociceptive processing is chemokine ligand 5 (CCL5) and its receptors, including chemokine receptor 5 (CCR5), which have been implicated in neuropathic 38, 39, 41 and bone cancer 23, 24 pain. Functional interactions occur between the mu-opioid receptor (MOR) and CCR5, 11, 16, 36, 40, 48, 58, 63 although the precise mechanisms are unclear. One possibility is that this occurs through formation of a heteromer, as evidence exists for heterodimerization of MOR and CCR5. 11, 61 MCC22 was therefore developed to target the putative MOR-CCR5 heteromer. 2 The pharmacophores in MCC22 include the MOR agonist oxymorphone, 72 and the CCR5 antagonist, TAK-220. 64 These pharmacophores are linked by a 22-atom spacer that confers optimal antinociception in mouse models of inflammatory pain. 2 Its potency was much greater than that of morphine and was several orders of magnitude more potent than any of its homologs with shorter spacers. Also, the fact that MCC22 was ;3600-fold more potent than a mixture consisting of Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
the monovalent mu agonist and the CCR5 antagonist ligand, suggest MOR-CCR5 heteromer as a target. Furthermore, MCC22 was much more potent when administered intrathecally as compared to the brain, 2 suggesting the spinal cord as a primary site of action for its analgesic effects.
We examined the antinociceptive effects of MCC22 in HbSS Townes mice and underlying mechanisms. MCC22 potently attenuated hyperalgesia without tolerance, decreased proinflammatory cytokines and increased the anti-inflammatory cytokine, IL-10, in the spinal cord, and decreased evoked responses of nociceptive dorsal horn neurons.
Methods

Animals
Adult, male Townes transgenic mice (4-12 weeks of age, 20-25 g) which exclusively express human sickle hemoglobin (HbSS), human hemoglobin heterozygotes (HbAS), and normal human hemoglobin (HbAA controls) were used in this study. Genotypes were confirmed by polymerase chain reaction per the Jackson Laboratory protocol and high performance liquid chromatography. 56 Mice were housed with 4 mice per cage, maintained on a 12-hour light-dark cycle, and had access to food and water ad libitum. The 3 mouse strains, HbAA, HbAS, and HbSS, were used to characterize mechanical hyperalgesia in all strains of Townes mice, whereas only the more severe hyperalgesic HbSS mice and controls were used to evaluate drug effects. Mice were randomly selected to treatments and conditions. All procedures were approved by the University of Minnesota Institutional Animal Care and Use Committee.
Drugs and administration
All compounds were synthesized as described previously.
2
MCC22 consists of a mu-opioid pharmacophore derived from the mu-opioid agonist, oxymorphone, linked through a 22-atom spacer to the CCR5 antagonist pharmacophore, TAK220 (1- 
MCC22 was initially dissolved in 10% dimethyl sulfoxide (Fisher Scientific, Hampton, NH) and was diluted to less than 1% dimethyl sulfoxide before administration. Homologs of MCC22 with spacer lengths of 14 and 24 atoms served as controls. Morphine (Mallinckrodt Inc, Hazlewood, MO) was dissolved in distilled water. All compounds were administered intraperitoneally (i.p.) to determine peak time and ED 50/80 values. Once determined, the ED 80 doses were used for all experiments.
Behavioral measures of mechanical hyperalgesia
Cutaneous mechanical hyperalgesia was assessed as described previously. 2, 8, 10, 31 The frequency of paw withdrawal evoked by a calibrated von-Frey monofilament (North Coast Medical, Inc, Gilroy, CA) with a bending force 9.3 mN applied to the plantar surface of the hind paws for 1 to 2 seconds was determined. Mice were placed beneath individual glass containers on a raised wire mesh surface and allowed to habituate for 15 minutes. The monofilament was applied to each hind paw 10 times at intervals of at least 3 seconds, and the average number of withdrawal responses was determined for each paw. Mechanical withdrawal threshold was determined using a pressure meter 13 consisting of a hand-held force transducer fitted with a polypropylene tip (electronic von Frey anesthesiometer; IITC Inc, Life Science Instruments, Woodland Hills, CA). The intensity of the stimulus was automatically recorded on paw withdrawal. Withdrawal threshold was defined as the mean from 3 trials. The experimenter was blinded to the treatment condition.
Mechanical hyperalgesia in deep tissues was assessed by determining forepaw grip force measured using a computerized grip force meter (Chatillon Ametek, Largo, FL), as we described previously, 8, 31 each mouse was held by its tail and gently passed over a wire mesh grid. The peak force was recorded in grams. Grip force was defined as the mean from 3 trials.
Electrophysiology
Electrophysiological recordings were made from nociceptive dorsal horn neurons as described previously. 10 Mice were anesthetized with 2.0% isoflurane (Kent Scientific, Torrington, CT) and given dexamethasone (5.0 mg/kg, subcutaneously) to prevent swelling and continuous saline (0.2 mL/h 2 ) to maintain hydration. A feedback-controlled heating pad (Physitemp Instruments, Inc, Clifton, NJ) was used to maintain core body temperature at ;37˚C. Respiration rate and blood pressure were monitored continuously. After depilation, an incision was made over the thoracic and lumbar regions of the vertebral column, a laminectomy exposed the lumbar enlargement at L4-L5, and mice were secured in a spinal frame. Isoflurane was reduced to 0.8% to 1.2%, and a reservoir around the spinal column was made of vinyl polysiloxane dental impression material (3M ESPE Dental Products, St. Paul, MN) and filled with warm artificial cerebrospinal fluid. After removal of the dura mater, extracellular recordings were made from dorsal horn neurons with receptive fields (RFs) located on the plantar surface of the hind paw using glass microelectrodes (;1 mV; Kation Scientific, Minneapolis, MN) lowered into the spinal cord in 3-mm steps using an electric microdrive (Kopf, Tujunga, CA). Action potentials were amplified, audiomonitored, and displayed on a storage oscilloscope. Receptive fields of dorsal horn neurons were searched for by lightly stroking the skin and applying mild pressure with the experimenter's fingers. Neurons were functionally classified as low threshold, wide-dynamic-range (WDR), or high-threshold cells using mechanical stimulation of graded intensities (brushing, light and strong pressure using fine arterial clips, and pinch with forceps), as described previously. 10 Receptive field areas were mapped using suprathreshold von-Frey monofilaments and drawn on a schematic of the hind paw. Only WDR neurons with action potentials easily discriminated by amplitude and shape were studied.
RNA isolation and real-time PCR
Mice underwent cardiac perfusion with phosphate-buffered saline (PBS), and spinal cords were removed (4 mice per group). RNA was isolated from whole spinal cords using Trizol and was treated with DNAse (Invitrogen, Amsterdam, the Netherlands) and was converted into cDNA using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers with the Advantage RT for PCR Kit (Takara Bio, Mountain View, CA). Real-time PCR reactions were conducted with Rotor-Gene SYBR Green PCR kit (Qiagen, Germantown, MD). Briefly, 0.5 mM primers, 1X SYBR Green Master Mix, and 2 mL diluted cDNA were combined, and reactions were conducted in triplicates. The primers sequences have been previously published. 46 Real-time PCR was conducted on a Qiagen Q real-time PCR machine using a hot start with cycle conditions, 40 cycles; 95˚C 15 seconds, 60˚C 10 seconds, and 72˚C 15 seconds; followed by a melt from 75 to 95˚C. Quantitation of the mRNA was based on standard curves derived from cDNA standards for each primer set from 1 fg/mg of RNA to 100 ng/mg of RNA. Positive and negative cDNA controls were used for each primer set derived from known cell sources for each cytokine. Samples were normalized to the expression of b-actin.
Experimental design
Antihyperalgesia
In separate groups of mice, withdrawal response frequencies were determined before treatment and ED 50/80 doses were established for i.p. administration. For each injection, withdrawal frequencies were determined at various times after injection to determine the duration of antihyperalgesia produced by each dose. In some experiments, MCC22 was given daily for up to 9 days to determine whether MCC22 exhibited acute or chronic tolerance.
Tolerance
HbSS mice received 2 i.p. injections daily (1 in the morning and 1 in the afternoon, 6 hours apart) of MCC22 8.0 mmoles/kg (10 mg/ kg) or morphine 26.4 mmoles/kg (10 mg/kg) for 9 consecutive days, and withdrawal response frequencies were determined before injection, and on treatment days 1, 3, and 9, at 30 minutes after the second injection. Withdrawal response frequencies were determined before and at 30 minutes after MCC22.
Electrophysiology
Once a nociceptive neuron was identified, spontaneous and evoked responses were obtained before any injection, 30 minutes after i.p. administration of vehicle, and at 30 minutes after i.p. administration of MCC22. First, the discharge rate (impulses/s) of ongoing, spontaneous activity was determined for a period of 3 minutes. Next, mechanical response thresholds were determined using von-Frey monofilaments. Threshold (mN) was defined as the weakest force to evoke a response that was clearly above any ongoing activity in at least 50% of the trials (8-10 trials). To obtain responses evoked by suprathreshold stimuli, an increasing series of von-Frey monofilaments (1.0, 8.0, and 15.0 g; 9.3, 73.6, and 135.3 mN, respectively) were each applied 3 times for 5 seconds in ascending order. Each stimulus was applied to random locations within the RF with an interstimulus interval of at least 30 seconds. Next, heat (30-50˚C) and cold (30-5˚C) stimuli were applied to the RF using a Peltier-type thermode (5 mm   2 ).
Beginning from a base temperature of 30˚C, stimuli were delivered with a continuous ramp at a rate of 2.0˚C/s and maintained for 1 second. Action potentials were discriminated using Spike II software (Cambridge Electronic Design, Cambridge, United Kingdom), and were stored on a computer along with the time of mechanical stimulation, and digitized traces of heat and cold stimuli.
Cytokine expression
HbSS mice received twice daily injections of the ED 80 dose of MCC22 or PBS (vehicle) for 9 consecutive days. The spinal cords were removed from HbSS mice administered MCC22 or PBS and from HbAA mice (4 mice per group). The RNA was isolated and converted to cDNA for use in real-time PCR (triplicates) with primers for IL-1b, IL-6, IL-10, and TNFa. Samples were normalized based on expression of b-actin.
Data analyses
Parametric statistics were used for all studies because data were normally distributed and displayed equal variance.
Behavior
Data are shown as mean (6SEM) values unless otherwise stated. Differences in withdrawal response thresholds, withdrawal response frequencies, and grip force between mouse strains were determined using 1-way analysis of variance (ANOVA). Drug effects on the magnitude and duration of antihyperalgesia, and tolerance, were compared between groups using 1-way ANOVA. Post hoc comparisons were made using Bonferroni t tests. A probability value of P , 0.05 was considered significant.
Electrophysiology
Comparisons were made in the responses of WDR neurons obtained in control, vehicle, and drug conditions. Mechanical response thresholds were compared by 1-way ANOVA. Discharge rates evoked by mechanical (von Frey) stimuli were determined by subtracting ongoing discharge rate during 10 seconds before the stimulus from the response that occurred during the stimulus (5 seconds) and for 5 seconds after. For each cell, mean responses evoked by each stimulus were obtained from 3 trials. Discharge rates evoked by each of the monofilaments for all neurons were compared between conditions using 2-way ANOVA with repeated measures. Bonferroni t tests were used for all post hoc comparisons. , and (C) mean forelimb grip (n 5 18) in Townes AA, AS, and SS mice. *A significant difference from AA mice; Bonferroni t test; P , 0.001; #a significant difference from AS mice; Bonferroni t test; P , 0.001.
Cytokine expression
The expression of specific mRNA was determined using standard curves for each primer set. Samples were normalized based on b-actin expression. Significant differences between HbAA mice and between HbSS mice-administered vehicle vs MCC22 was determined using 1-way ANOVA with Bonferroni t tests (P , 0.05).
Results
Townes sickle mice exhibit robust mechanical hyperalgesia
As shown previously, 37 HbSS Townes mice exhibited hyperalgesia indicated by a decrease in paw withdrawal threshold, an increase in paw withdrawal frequency, and a decrease in forelimb grip force as compared to HbAS and HbAA controls (Fig. 1) . HbSS mice had lower mechanical withdrawal thresholds compared with both HbAS and HbAA mice ( Fig. 1B; 1-way ANOVA, F(2, 105) 5 59.39, P , 0.001), whereas withdrawal thresholds did not differ between HbAS and HbAA mice. Also, both HbSS and HbAS mice exhibited greater paw withdrawal frequencies than control HbAA mice, although withdrawal frequency in HbAS mice was less than that of HbAS mice ( Fig.  1A; 1-way ANOVA, F(2, 33) 5 123.11, P , 0.001). Similarly, HbSS and HbAS mice had lower forelimb grip force compared with HbAA mice (Fig. 1C; 1-way ANOVA, F(2, 51) 5 31.13, P , 0.001), although this was more pronounced in HbSS mice (P , 0.001).
MCC22 produces dose-dependent and long-lasting antihyperalgesia in sickle mice
We compared efficacies of MCC22 and morphine in HbSS mice. Both MCC22 and morphine reduced mechanical hyperalgesia dose dependently. The ED 50 for MCC22 was 0.88 mmol/kg, which was lower than that of morphine (5.84 mmol/ kg; Fig. 2A ; 1-way ANOVA, F(6, 77) 5 127.69, P , 0.001). MCC22 also produced a longer duration of antihyperalgesia than morphine ( minutes after injection and peaked at 30 minutes. MCC22 produced a maximal reduction in paw withdrawal frequency of more than 90% in HbSS mice that persisted for at least 4 hours after injection, at which time there was still approximately 30% inhibition of hyperalgesia. Paw withdrawal frequency returned to preinjection values at 24 hours. Antihyperalgesia after the ED 80 dose for morphine (26.4 mmol/kg; 10 mg/kg) peaked at 30 minutes and produced a maximal reduction in paw withdrawal frequency of 73.0%. After morphine, hyperalgesia recovered more quickly as compared to MCC22, and there was a 41% inhibition of hyperalgesia 1 hour after injection, as compared to 30% at 4 hours after MCC22. Hyperalgesia recovered by 2 hours after injection of morphine and did not differ from baseline.
MCC22 did not produce tolerance to its antihyperalgesic effect
It is well known that tolerance occurs with repeated administration of opioids resulting in the need for higher doses that limit their use. Therefore, we examined the extent to which tolerance occurred after repeated administration of MCC22 and compared this with morphine. We compared the antihyperalgesia produced by repeated administration of the ED 80 dose for MCC22 (8.0 mmol/kg) with that produced by repeated administration of the ED 80 dose for morphine (26.4 mmol/kg) in separate groups of HbSS mice. Mice were given twice daily injections of either MCC22 or morphine for 9 consecutive days. Withdrawal response frequencies were determined before and at 30 minutes after injection of MCC22 (Fig. 3A) or morphine (Fig. 3B ) on day 1, 3, and 9 of treatment. Tolerance was not observed after MCC22 and consistently produced maximal antihyperalgesia over the 9-day time course (1-way ANOVA with repeated measures, F(5, 39) 5 237.43, P , 0.001). Unexpectedly, during this period, baseline withdrawal response frequencies gradually decreased in MCC22-treated mice. By contrast, morphine exhibited tolerance as early as day 3 (1-way ANOVA with repeated measures, F(5, 38) 5 38.84, P , 0.001) and did not produce any antihyperalgesia by day 9 of treatment. These results show that unlike morphine, MCC22 does not produce tolerance to its antihyperalgesic properties over the 9-day time course. www.painjournalonline.com
Evoked responses of dorsal horn neurons in sickle mice were reduced by MCC22
Eight mechanosensitive WDR neurons were studied from 8 HbSS mice. Recording sites were in the dorsal horn at depths from 243 to 588 mm below the surface of the spinal cord. Receptive fields were located on the plantar surface of the hind paw. None of the neurons were spontaneously active, and 2 were responsive to heat stimuli, and 2 were excited by cold stimuli. Evoked responses were obtained before any drug injection, at 30 minutes after vehicle injection, and at 30 minutes after MCC22 (8 mmol/ kg). MCC22, but not vehicle, dramatically decreased evoked responses to mechanical and thermal stimuli. Figure 4A As seen in Figure 4 , the extent to which MCC22 decreases mean discharge rates is significantly greater with increasing levels of von-Frey filaments. MCC22 also increased mean response thresholds for all neurons (1-way ANOVA, F(2, 21) 5 10.33, P , 0.001). Mean response thresholds did not change after injection of vehicle (4.7 6 0.44 mN before and 5.0 6 0.43 mN after) but increased to 7.9 6 0.74 mN after injection of MCC22 (the Bonferroni t test, P , 0.004). A representative example of the functional characterization (Fig. 4B) and mechanically evoked responses before and after injection of vehicle and MCC22 for a single WDR neuron is illustrated in Figures 4C-E . Four of the 8 WDR neurons studied were also responsive to noxious cold (5˚C; n 5 2) and to noxious heat (50˚C; n 5 2). Responses of individual WDR neurons to cold and heat are illustrated in Figures 5A and B , respectively, and were not altered after administration of vehicle but were greatly reduced after MCC22.
MCC22 reduces proinflammatory cytokines and increases anti-inflammatory cytokines in the spinal cord
Proinflammatory cytokines released by activated microglia contribute to sensitization of nociceptive neurons in the spinal cord. Proinflammatory cytokines have been associated with chronic pain, including neuropathic pain. We determined whether MCC22 decreased proinflammatory cytokines and/or increased anti-inflammatory cytokines as a possible mechanism for its antihyperalgesic effect. HbSS mice with mechanical hyperalgesia that were treated twice daily for 9 days with vehicle had increased expression of the proinflammatory cytokines, IL-1b, IL-6, and TNFa, in the spinal cord as compared to HbAA mice (Fig. 6) . Oneway ANOVAs showed that the expression of these cytokines was decreased significantly in HbSS mice given MCC22 (8 mmol/kg) twice daily for 9 consecutive days (IL-1b; F(2, 6) 5 1310.0, P , 0.0001; IL-6; F(2, 6) 5 1273.0, P , 0.0001; TNFa; F(2, 6) 5 1376.0, P , 0.0001). Thus, microglia are a possible target for MCC22 because they express both MOR and CCR5. Figure 6 shows that expression of the anti-inflammatory cytokine, IL-10, in the spinal cord was increased after MCC22 as compared to HbAA mice and HbSS mice-treated with vehicle for 9 days (1-way ANOVA, F(2, 6) 5 754.1, P , 0.0001). IL-10 has been shown to decrease hyperalgesia in inflammatory and neuropathic pain models. 35, 43, 52, 76 Thus, the increase in IL-10 may contribute to the analgesic efficacy of MCC22.
Discussion
Targeting multiple receptors with multifunctional or bivalent ligands may be an effective approach for treating pain. Ligands that target opioid/NK-1, 59 opioid/nociceptin, 60 opioid/ CB1, 33, 44 opioid/metabotropic glutamate receptor-5, 57 and multiple opioid receptors 1, 34, 53 were found to be effective analgesics having enhanced potency in preclinical models. MCC22 differs from previous ligands in that it targets mu opioid and a chemokine receptor, CCR5. This makes MCC22 unique because it targets CCR5 (and MOR) on glial cells to inhibit glial activation and proinflammatory cytokines that contribute to central sensitization, and MOR located on neurons (and perhaps glia) to decrease neuronal excitability. Although direct binding studies have not been conducted, molecular modeling and simulation studies suggest that MCC22 is capable of binding to both MOR and CCR5. 2 The combined action of Figure 3 . MCC22 does not produce tolerance to its analgesic effect. HbSS mice were treated twice daily with intraperitoneal injections of 8 mmol/kg (10 mg/kg) MCC22 (n 5 8-12) (A) or 26.4 mmol/kg (10 mg/kg) morphine (n 5 6-11) (B) for 9 consecutive days and paw withdrawal frequency was determined before and at 30 minutes after the second injection on days 1, 3, and 9. No analgesic tolerance occurred in mice given MCC22, whereas complete tolerance developed in mice that received morphine. *A significant difference from baseline (preinjection) values (Bonferroni t tests; P , 0.001). #A significant difference from day 1 baseline (Bonferroni t tests; P , 0.001). &A significant difference from baseline day 3 (Bonferroni t tests; P , 0.01).
MCC22 on glial cells and neurons may account for its extraordinary potency. Opioids are a primary treatment for chronic, severe pain in patients with SCD. Given the many undesirable side effects associated with opioids, new approaches for managing severe chronic pain are needed. The results of this study show that the novel bivalent ligand, MCC22, which targets MORs and CCR5, produced dose-dependent, potent antihyperalgesia in a transgenic mouse model of SCD. Importantly, MCC22 did not produce analgesic tolerance, at least over a 9-day period when given twice per day, whereas administration of morphine given over the same time course resulted in substantial tolerance.
Psychophysical studies using quantitative sensory testing have shown that patients with SCD have greater sensitivity to mechanical, heat, and cold stimuli 7 that is likely due to both peripheral and central mechanisms. For example, in the periphery, sickle mice exhibited increases in immunoreactivity for substance P and calcitonin gene-related peptide (neuropeptides found in nociceptive neurons), neurogenic inflammation, activation of mast cells, nerve sprouting, decreased innervation (indicative of neuropathy), and sensitization of nociceptors. 27, 31, 66, 69 In the spinal cord, sickle mice had elevated phosphorylated MAP kinases, activated astrocytes and microglia, and upregulation of TLR4, IL-6, STAT3, and COX-2.
31,68
These changes, as well as increases in proinflammatory cytokines IL-1b, IL-6, and TNFa found in this study likely contribute to the increased responses of dorsal horn neurons (central sensitization) described in sickle mice. 10 Similarly, patients with SCD also had elevated plasma levels of cytokines that include IL-1b, IL-6, and TNFa, and substance P, 9, 54 and psychophysical studies of pain tolerance and central summation of evoked pain suggested that pain in SCD is associated with central sensitization. 9 In addition to inflammatory pain, neuropathic pain has been described in sickle mice as evidenced by decreased cutaneous innervation, 31 and nearly 40% of patients had evidence of neuropathic pain based on sensory symptoms. 6 The antihyperalgesia produced by MCC22 in this study was concomitant with a decrease in the expression of proinflammatory cytokines in the spinal cord and decreased evoked responses of nociceptive dorsal horn neurons. Interactions between glia and neurons contribute to hyperalgesia through the release of proinflammatory cytokines from glial cells that sensitize proximal dorsal horn neurons. 21, 65, 75 It is possible that MCC22 blocks this process by reducing the release of the proinflammatory cytokines IL-1b, IL-6, and TNFa, which contribute to central sensitization. 3, 30 Interestingly, MCC22 also increased the expression of the anti-inflammatory cytokine, IL-10, which might represent a compensatory mechanism associated with the increase in the proinflammatory cytokines produced by the disease, or be a direct effect of MCC22. Indeed, targeting specific inflammatory pathways is a general therapeutic approach for SCD. The specific 22-atom linker requirement for the extraordinary potency of MCC22-produced antihyperalgesia and the results of molecular simulation studies have suggested the targeting of an MOR-CCR5 heteromer. 2 The spacer length was based on previous studies that suggested effective bridging of heteromeric G-protein-coupled receptor (GPCR) protomers in the range of 18 to 22 atoms 77 and on molecular simulation studies of the interaction of MCC22 with an MOR-CCR5 heteromer, which were consistent with bridging of MOR and CCR5 protomers. The ability for GPCRs to form heteromers has been established. 17, 22 Receptor heterodimerization can alter receptor function, ligand pharmacology, signal transduction, and cellular trafficking. 26 Thus, targeting GPCR heteromers may result in more potent compounds that selectively act on cells that coexpress both receptors. 28 With respect to opioid receptors, it has been shown that they can form heteromers with a number of different GPCRs and that the propensity for MORs to form dimers with other GPCRs may be modulated in pathological states. 20 It is known that MOR interacts with other GPCRs through the formation of heteromers. 20 For example, mu-delta (MOR-DOR) opioid receptor heteromers have been identified and ligands targeting this heteromer produced potent analgesia. 1, 74 MMG22, another bivalent ligand consisting of mu-opioid agonist and metabotrophic glutamate receptor 5 antagonist pharmacophores, displayed exceptionally potent antinociception after intrathecal administration in mouse models of acute inflammatory pain and cancer pain without the side effects associated with clinically used opioids. 57 Importantly, there is evidence that MOR-CCR5 heteromers may exist in vivo. Both receptors are present in neurons and glia in the dorsal horn and are colocalized in other areas of pain processing. 25, 36 Thus, functional interactions between MOR and CCR5 receptors located on glia and/or neurons may contribute to chronic pain, perhaps by desensitization of MOR on activation of CCR5. 62 Because proinflammatory cytokines from activated microglia in the spinal cord contribute to hyperalgesia through central sensitization, targeting an MOR-CCR5 heteromer with concomitant activation of MOR and blockade of CCR5 was considered as an approach to inhibiting activated microglia for developing effective analgesics for chronic pain. 2 Significantly, MCC22 given daily for 9 days reduced the enhanced expression of proinflammatory cytokines in the spinal cord of sickle mice. It is unknown from these studies whether the decrease in cytokines after MCC22 contributed to the decrease in responses of dorsal horn neurons. Also, it is not known whether a decrease in proinflammatory cytokines contributes to the decrease in hyperalgesia and responses of dorsal horn neurons after a single injection of MCC22 or whether these changes occur through a different mechanism. However, a cytokine-related mechanism is a possibility because there is ongoing inflammation in sickle mice and in patients. It is unclear how MCC22 produced a profound decrease in proinflammatory cytokines, but previous studies showing that chronic intrathecal administration of a CCR5 antagonist decreased neuropathic pain, also reported a decrease in proinflammatory and an increase in anti-inflammatory cytokines in the spinal cord. 50 Indeed, antinociception produced by MCC22 was blocked by the microglia inhibitor, minocycline, 2 suggesting that MCC22 might interact with activated glial cells and thereby reduce excitability of dorsal horn neurons. Further studies are needed to elucidate specific effects of MCC22 on glial cells and their neuronal interactions.
A common side effect of clinically used opioids is tolerance that leads to the need for elevated doses to achieve the desired effect. 15 Remarkably, tolerance was not observed after repeated daily administration of MCC22, and baseline paw withdrawal frequencies unexpectedly decreased over time. Although it is unclear why baseline withdrawal responses decreased over time after repeated administration of MCC22, this may be related to the pharmacokinetic excretion of MCC22 or modulation of the MOR-CCR5 heteromer with repeated activation. Intrinsic receptor mechanisms such as receptor internalization and desensitization contribute to opioid tolerance, 73 and it is unknown whether MCC22 alters the kinetics and receptor trafficking that lead to downregulation or desensitization of MOR. In this regard, it was reported that blockade of microglia reduced opioid tolerance and increased analgesic efficacy. 71 In conclusion, our studies indicate that MCC22 produced potent antinociception in sickle mice and decreased responses of nociceptive dorsal horn neurons. These changes were associated with decreased levels of proinflammatory cytokines (IL-1b, IL-6, and TNFa) and increased levels of the anti-inflammatory cytokine, IL-10, in the spinal cord. The finding that MCC22 was highly effective in inhibiting hyperalgesia without producing tolerance in hyperalgesic sickle mice suggests potential use for treatment of other painful inflammatory and neuropathic disorders. Strategic targeting of heteromers may be an effective alternative to traditional opioids for the treatment of chronic pain conditions.
